Cyclic nucleotide phosphodiesterase inhibitors: possible therapeutic drugs for female fertility regulation

Eur J Pharmacol. 2020 Sep 15:883:173293. doi: 10.1016/j.ejphar.2020.173293. Epub 2020 Jul 12.

Abstract

Cyclic nucleotide phosphodiesterases (PDEs) are group of enzymes responsible for the hydrolysis of cyclic adenosine 3', 5' monophosphate (cAMP) and cyclic guanosine 3', 5' monophosphate (cGMP) levels in wide variety of cell types. These PDEs are detected in encircling granulosa cells or in oocyte with in follicular microenvironment and responsible for the decrease of cAMP and cGMP levels in mammalian oocytes. A transient decrease of cAMP level initiates downstream pathways to cause spontaneous meiotic resumption from diplotene arrest and induces oocyte maturation. The nonspecific PDE inhibitors (caffeine, pentoxifylline, theophylline, IBMX etc.) as well as specific PDE inhibitors (cilostamide, milrinone, org 9935, cilostazol etc.) have been used to elevate cAMP level and inhibit meiotic resumption from diplotene arrest and oocyte maturation, ovulation, fertilization and pregnancy rates both in vivo as well as under in vitro culture conditions. The PDEs inhibitors are used as powerful experimental tools to demonstrate cyclic nucleotide mediated changes in ovarian functions and thereby fertility. Indeed, non-hormonal nature and reversible effects of nonspecific as well as specific PDE inhibitors hold promise for the development of novel therapeutic drugs for female fertility regulation.

Keywords: Cyclic nucleotides; Fertility regulation in mammals; Oocyte maturation; PDEs inhibitors.

Publication types

  • Review

MeSH terms

  • Animals
  • Female
  • Fertility / drug effects*
  • Fertility Agents, Female / therapeutic use*
  • Humans
  • Infertility, Female / drug therapy*
  • Infertility, Female / enzymology
  • Infertility, Female / physiopathology
  • Oocytes / drug effects*
  • Oocytes / enzymology
  • Ovary / drug effects*
  • Ovary / enzymology
  • Ovary / physiopathology
  • Ovulation / drug effects
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Pregnancy

Substances

  • Fertility Agents, Female
  • Phosphodiesterase Inhibitors